Recombinant Human TNFSF13B/BAFF/CD257 Protein

Catalog No.: RP01730

Sequence Information

Species	Gene ID
human	10673
Swiss Prot	**Tags**
Q9Y275	N-6His

Synonyms
DTL; BAFF; BLYS; CD257; TALL1; THANK; ZTNF4; TALL-1; TNLG7A; TNFSF20;TNFSF13B

Product Information

Source	Purification
HEK293 cells	≥ 90 % as determined by SDS-PAGE.
Calculated MW	**Observed MW**
17.88 kDa	19-20 kDa

Endotoxin
< 0.1 EU/μg of the protein by LAL method.

Formulation
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

Reconstitution
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Background

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sj?gren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

Basic Information

Description
Recombinant human TNFSF13B/BAFF/CD257 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala134-Leu285) of human TNFSF13B/BAFF/CD257 (Accession #NP_006564.1) fused with a 6×His tag at the N-terminus.

Activity
Measured by its binding ability in a functional ELISA.Immobilized Human TNFSF13B (Catalog: RP01730) at 5 μg/mL (100 μL/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.

Shipping
Lyophilized proteins are shipped at ambient temperature.
Liquid proteins are shipped at frozen temperature with dry ice.
Upon receipt, store it immediately at the temperature recommended below.

Storage
Store at -20℃


Operational Notes
For your safety and health, please wear a lab coat and disposable gloves for handling.

Contact


400-999-6126
cn.market@abclonal.com.cn
www.abclonal.com.cn

For research use only. Not for therapeutic or diagnostic purposes.
Please visit http://abclonal.com for a complete listing of recommended products.

Validation Data



Immobilized Human TNFSF13B (Catalog: RP01730) at 5 μg/mL (100 μL/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.



Recombinant Human TNFSF13B/BAFF/CD257 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.